Celgene's Kyprolis Draws Focus Away From Amgen

Bank of America Merrill Lynch biotech analyst Rachel McMinn commented on how an increased focus on Celgene's (NASDAQ: CELG ) Kyprolis Cardiovascular toxicities among centers have stolen the spotlight from Amgen (NASDAQ: AMGN ). RBC reported on Wednesday that Amgen's PCSK9 inhibitor has a 75 percent probability that